Posted by Michael Wonder on 21 Apr 2021
Additional analysis of Luxturna in the treatment of visual impairment caused by hereditary eye disease
21 April 2021 - TLV has made a supplementary analysis to the previous evaluation of Luxturna, as Novartis has submitted new clinical data and a revised health economic analysis where costs linked to, among other things, travel services, assistance and the purchase of aids are now taken into account.
These new clinical data include longer follow-up time from a clinical study, up to four years of data, as well as short-term results from patients treated with Luxturna outside the clinical studies.
